Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-05
2011-04-05
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100
Reexamination Certificate
active
07919088
ABSTRACT:
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
REFERENCES:
patent: 4883666 (1989-11-01), Sabel et al.
patent: 5576184 (1996-11-01), Better et al.
patent: 5589154 (1996-12-01), Anderson
patent: 5753624 (1998-05-01), McMichael
patent: 5780587 (1998-07-01), Potter
patent: 5807741 (1998-09-01), Brown et al.
patent: 5851996 (1998-12-01), Kline
patent: 5958883 (1999-09-01), Snow
patent: 6504080 (2003-01-01), Van Der Putten
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6761888 (2004-07-01), Schenk
patent: 6787523 (2004-09-01), Schenk
patent: 6946135 (2005-09-01), Schenk et al.
patent: 6972127 (2005-12-01), Schenk
patent: 7014855 (2006-03-01), Schenk
patent: 7306945 (2007-12-01), Chilcote et al.
patent: 7358331 (2008-04-01), Chilcote et al.
patent: 7479482 (2009-01-01), Frangione et al.
patent: 7674599 (2010-03-01), Chilcote et al.
patent: 2002/0094335 (2002-07-01), Chalifour et al.
patent: 2002/0151464 (2002-10-01), Wolozin et al.
patent: 2002/0160394 (2002-10-01), Wu
patent: 2002/0187157 (2002-12-01), Jensen et al.
patent: 2002/0197258 (2002-12-01), Ghanbari et al.
patent: 2003/0086938 (2003-05-01), Jensen et al.
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: 2003/0166558 (2003-09-01), Frangione et al.
patent: 2003/0185827 (2003-10-01), Rodriguez et al.
patent: 2004/0136993 (2004-07-01), Schenk et al.
patent: 2004/0146521 (2004-07-01), Schenk et al.
patent: 2004/0197831 (2004-10-01), Weksler et al.
patent: 2005/0123544 (2005-06-01), Schenk et al.
patent: 0 613 007 (1994-08-01), None
patent: 1 633 189 (2006-03-01), None
patent: WO 91/16819 (1991-11-01), None
patent: WO 95/06407 (1995-03-01), None
patent: WO 99/06545 (1999-02-01), None
patent: WO 99/06545 (1999-02-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/40191 (1999-08-01), None
patent: WO 99/50300 (1999-10-01), None
patent: WO 99/60024 (1999-11-01), None
patent: WO 00/18917 (2000-04-01), None
patent: WO 00/18917 (2000-04-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 01/06989 (2001-02-01), None
patent: WO 01/06989 (2001-02-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/60794 (2001-08-01), None
patent: WO 01/60794 (2001-08-01), None
patent: WO 02/03911 (2002-01-01), None
patent: WO 03/000714 (2003-01-01), None
patent: WO 03/000714 (2003-01-01), None
patent: WO 03/045128 (2003-06-01), None
patent: WO 03/045128 (2003-06-01), None
patent: WO 2004/009625 (2004-01-01), None
patent: WO 2004/009625 (2004-01-01), None
patent: WO 2004/041067 (2004-05-01), None
patent: WO 2004/041067 (2004-05-01), None
patent: WO 2005/013889 (2005-02-01), None
patent: WO 2005/047860 (2005-05-01), None
patent: WO 2005/047860 (2005-05-01), None
patent: WO 2006/020581 (2006-02-01), None
patent: WO 2006/020581 (2006-02-01), None
patent: WO 2006/045037 (2006-04-01), None
patent: WO 2006/045037 (2006-04-01), None
patent: WO 2007/011907 (2007-01-01), None
patent: WO 2007/012061 (2007-01-01), None
patent: WO 2007/021255 (2007-02-01), None
patent: WO 2008/103472 (2008-08-01), None
U.S. Appl. No. 11/894,772, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/894,744, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/894,605, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/842,054, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/841,996, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/697,646, filed Apr. 6, 2007, Schenk et al.
U.S. Appl. No. 11/710,248, filed Feb. 23, 2007, Schenk et al.
U.S. Appl. No. 11/660,015, filed Feb. 9, 2007, Schenk et al.
U.S. Appl. No. 10/850,570, filed May 19, 2004, Chilcote et al.
U.S. Appl. No. 60/518,140, filed Nov. 8, 2003, Chilcote et al.
U.S. Appl. No. 60/471,929, filed May 19, 2003, Chilcote et al.
Abbas et al.,Cellular and Molecular Immunology, 522-523 (Elsevier Saunders) (5th Ed. Updated Ed., 2005).
Anderson et al., “Phosphorylation of SER-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease,” The Journal of Biological Chemistry, 281:29739-29752 (2006).
Alves da Costa, “Recent Advances on α-Synuclein Cell Biology : Functions and Dysfunctions,” Current Molecular Medicines, 3:17-24 (2003).
Bales et al., “Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody,”J. Clin. Invest., 116(3):825-832 (2006).
Bard et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nature Medicine, 6(8):916-919 (2000).
Bennett et al., “Degradation of α-Synuclein by Proteasome,”J. Biol. Chem., 274(48):33855-33858 (1999).
Bodles et al., “Toxicity of non-Aβ component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β-sheet structure and fibrils,”Eur. J. Biochem., 267:2186-2194 (2000).
Brooks et al., “Synuclein proteins and Alzheimer's disease,” Trends Neurosci., 17(10):404-405 (1994).
Cao et al., “Development of an Alpha Synuclein Recombinant Protein as a Potential Candidate Against Parkinson's Disease,” Program No. 594.3, Abstract Viewer/Itinerary Planner, Washington D.C.: Society for Neuroscience (2002).
Casadesus et al., “The Estrogen Myth; Potential Use of Gonadotropin-releasing hormone Agonists for Treatment of Alzheimer's Disease,” Drugs R&D, 7(3):187-193 (2006).
Chang et al., “Adjuvant activity of incomplete Freund's adjuvant,”Advanced Drug Delivery Reviews, 32:173-186 1998).
Chapman, “Model behavior,”Nature, 408:915-916 (2000).
Chen et al., “Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice,”Progress in Brain Research, 117:327-337 (1998).
Chilcote et al., “Comparison of alpha-synuclein species in Lewy bodies and the soluble fraction of diffuse Lewy body disease brain,” Database Biosis [Online] Biosciences Information Service, Phililadelphia, PA, US (2003) Abstract only.
Clayton et al., “Synucleins in Synaptic Plasticity and Neurodegenerative Disorders,”J. Neurosci. Res., 58:120-129 (1999).
Clayton et al, “The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration, and disease,”Trends Neurosci., 21(6):249-254 (1998).
Cleland et al., “Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21,”J.of Pharm Sci., 85(1): 22-28 (1996).
Conway et al., “Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy,” PNAS, 97(2):571-576 (2000).
Crowther et al., “Synthetic filaments assembled from C-terminally truncated a-synuclein,”FEBS Letters, 436:309-312 (1998).
Culvenor et al., “Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited, NAC and α-Synuclein are not Associated with Aβ Amyloid,”Am. J. Pathology, 155(4):1173-1181 (1999).
De Lustig et al., “Peripheral markers and diagnostic criteria in Alzheimer's disease: Critical evaluations,”Rev. in Neurosci., 5:213-225 (1994).
Demattos et al., “Peripheral Anti Aβ Antibody Alters CNS and Plasma Aβ Clearance and Decrease Brain Aβ Burden in a Mouse Model of Alzheimer's Disease,” published online before print Jul. 3, 2001 at 10.1073/pnas.151261398;PNAS, 98(15):8850-8855 (2001)
Buttini Manuel J.
Chilcote Tamie J.
Games Kate Dora
Masliah Eliezar
Rockenstein Edward
Alston & Bird LLP
Elan Pharmaceuticals Inc.
Kolker Daniel E
The Regents of the University of California
LandOfFree
Treatment and delay of onset of synucleinopathic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and delay of onset of synucleinopathic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and delay of onset of synucleinopathic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2723289